Stina Lundgren appointed as new CEO

Veltio Pharma has announced a significant leadership change with the appointment of Stina Lundgren as its new CEO. This move marks a new chapter for the company, promising fresh perspectives and renewed energy in its mission to advance pharmaceutical development. The decision reflects Veltio Pharma's commitment to growth and innovation in a competitive industry.

Photo: Stina Lundgren.

Who is Stina Lundgren?

Stina Lundgren brings extensive experience in pharmaceutical leadership and a track record of driving growth in healthcare companies. Before joining Veltio Pharma, she held senior roles in several well-known pharmaceutical firms, where she led teams focused on research, development, and commercialization.

Her background includes:

• Leading cross-functional teams to accelerate drug development timelines

• Building partnerships with research institutions and healthcare providers

• Managing regulatory submissions and compliance processes

• Driving strategic initiatives that increased company revenues and market share

  
  

Lundgren’s leadership style emphasizes collaboration, transparency, and a clear focus on patient needs. Her appointment signals Veltio Pharma’s intent to strengthen its research pipeline and expand its global reach.

“I’m excited to lead Veltio Pharma at this pivotal time. Our nanotechnology platform has great potential, and I look forward to enabling innovative treatments to market,” said Stina Lundgren.